Effect and safety analysis of Yiqi Yangxue Jiedu decoction combined with entecavir in the treatment of male patients with decompensated hepatitis B cirrhosis

Background: This study aimed to evaluate the efficacy and safety of Yiqi Yangxue Jiedu Decoction & Entecavir in male patients with decompensated hepatitis B cirrhosis. Methods: A retrospective analysis was conducted using clinical data from 195 male patients with decompensated hepatitis B cirrhosis treated at our hospital between February 2022 and February 2024. Based on treatment regimens, the patients were divided into the observation group (100 cases), treated with Yiqi Yangxue Jiedu Decoction and Entecavir, the control group (95 cases), treated with Entecavir. Both groups received standard Western medicine treatment. The clinical efficacy and safety of the treatments were compared. Results: The total effective rate in the observation group was significantly higher (p < 0.05). Among the observation group, patients with moderate liver cirrhosis exhibited a significantly higher total effective rate than those with severe liver cirrhosis, patients with low viral load demonstrated a significantly higher total effective rate than high viral load (p < 0.05). Post-treatment, the observation group showed significantly reduced alanine aminotransferase (ALT), total bilirubin (TBIL) levels and increased albumin (ALB) levels than the control group (p < 0.05). The observation group had significantly lower levels of type III procollagen (PC III), type IV collagen (IV-C), laminin (LN) and hyaluronic acid (HA) (p < 0.05), shorter prothrombin time (PT), higher prothrombin activity (PTA) post-treatment than control group (p < 0.05), while the incidence of adverse reactions was comparable of two groups (p < 0.05). After six months of follow-up, the observation group exhibited a significantly lower incidence of delayed adverse events (p < 0.05). Conclusions: The combination of Yiqi Yangxue Jiedu Decoction and Entecavir significantly improves treatment efficacy, enhances liver function recovery, reduces liver fibrosis in male patients with decompensated hepatitis B cirrhosis. The regimen also demonstrated good safety, supporting its potential for broader clinical application.

Yiqi Yangxue Jiedu decoction; Entecavir; Decompensated hepatitis B cirrhosis

[1] Jin Y, Wang S, Tang K, Zhan P, Liu X. Recent advances in screening methods enabling the discovery of novel anti-hepatitis B virus drug candidates. European Journal of Medicinal Chemistry. 2025; 282: 117093.

[2] Iannacone M, Guidotti LG. Immunobiology and pathogenesis of hepatitis B virus infection. Nature Reviews Immunology. 2022; 22: 19–32.

[3] McMahon BJ. Natural history of chronic hepatitis B. Clinics in Liver Disease. 2010; 14: 381–396.

[4] Shan S, Zhao X, Jia J. Comprehensive approach to controlling chronic hepatitis B in China. Clinical and Molecular Hepatology. 2024; 30: 135–143.

[5] Gülcicegi DE, Hannemann J, Bürger M, Allo G, Dittmann E, Martin A, et al. Spleen stiffness measurements during recompensation in patients with acutely decompensated liver cirrhosis: preliminary findings of a pilot study. Frontiers in medicine. 2024; 11: 1475997.

[6] Lan Y, Yu Y, Zhang X, Xu X, Yu X, Tu H, et al. Risk factors and prognostic impact of new decompensated events in hospitalized patients with decompensated cirrhosis. BMC Gastroenterology. 2024; 24: 408.

[7] Wang Z, Wang X, Zhou L, Shi S, Hua Y, Feng Y. Safety and efficacy of 48-week pegylated interferon-α-2b therapy in patients with hepatitis B virus-related compensated liver cirrhosis: a pilot observational study. Frontiers in Medicine. 2024; 11: 1489671.

[8] Wang H, Wu L. A comparison of the therapeutic efficacy of Tenofovir Disoproxil Fumarate and Entecavir in patients with chronic Hepatitis-B. Pakistan Journal of Medical Sciences. 2024; 40: 2390–2394.

[9] Tu A, Zhu X, Dastjerdi PZ, Yin Y, Peng M, Zheng D, et al. Evaluate the clinical efficacy of traditional Chinese Medicine as the neoadjuvant treatment in reducing the incidence of hepatocellular carcinoma in patients with hepatitis B-related cirrhosis: A systematic review and meta-analysis. Heliyon. 2024; 10: e24437.

[10] Eduku A, Dogbey VES. Seroprevalence of hepatitis B virus infection (HBsAg) and associated factors among antenatal clinic attendees in a secondary-level facility in southern Ghana. Clinical Epidemiology and Global Health. 2024; 26: 101553.

[11] Debsikréo N, Mankréo BL, Moukénet A, Ouangkake M, Mara N, Moussa AM, et al. Prevalence of hepatitis B virus infection and its associated factors among students in N’Djamena, Chad. PLOS ONE. 2024; 19: e0273589.

[12] Chinese Society of Hepatology of Chinese Medical Association. Chinese guidelines on the management of hepatic encephalopathy in cirrhosis (2024). Chinese Journal of Hepatology. 2024; 32: 799–812.

[13] Li S, Xiao W. General expert consensus on application of network pharmacology in research and development of new traditional Chinese medicine drugs. China Journal of Chinese Materia Medica. 2024; 49: 5055–5068. (In Chinese)

[14] Domínguez A, Avellón A, Hernando V, Soldevila N, Borràs E, Martínez A, et al. Hepatitis B virus-related cirrhosis and hepatocellular carcinoma hospital discharge rates from 2005 to 2021 in Spain: impact of universal vaccination. Vaccines. 2024; 12: 1254.

[15] Hong Y. Impact of nursing interventions based on self-efficacy theory on HAMA and HAMD scores in patients with hepatitis B cirrhosis. Journal of Clinical and Nursing Research. 2024; 8: 129–134.

[16] Cai X, Peng S, Xiao X, Huang Z, Zhang P. Serum ApoB/ApoA1 ratio in patients with CHB and the occurrence of HBV related cirrhosis and HBV related hepatocellular carcinoma. Scientific Reports. 2024; 14: 10996.

[17] Amal Mohammed AM, El-Hennawy AY, Hassan EH, Mohamed B, Abdelraouf A, Abdelhaleem A, et al. Detection of H-Pylori in the explanted liver tissue and the enlarged perihepatic lymph nodes of cirrhotic patients with decompensated end-stage liver disease recruited for liver transplantation. Asian Pacific Journal of Cancer Prevention. 2025; 26: 181–187.

[18] Fan LY. Impact of ALT changes on the risk of HCC in hepatitis B—compensated cirrhotic patients with low viremia. The American Journal of Gastroenterology. 2023; 118: 1701.

[19] Wang Y, Sun Y, Zhang W, Yao Y, Bian Z, Qian X. Relieving effect of jiao-tune of 5-element music on negative emotions in patients with decompensated hepatitis B virus cirrhosis: a randomized and controlled experiment study. Medicine. 2024; 103: e39556.

[20] Deng Y, Zheng H, Xiang H, Nan Y, Hu J, Meng Q, et al. On-treatment factors predict recompensation in entecavir-treated hepatitis B patients with decompensated cirrhosis. Journal of Hepatology. 2023; 78: S243.

[21] Zhang X, Zheng D, He L, Li W, Zhou W, Pang Z, et al. A clinic study on long-term efficacy and safety of autologous peripheral blood stem cell transplantation in patients with decompensated hepatitis B cirrhosis. Alternative Therapies in Health and Medicine. 2024; 30: 160–166.

[22] Zheng S, Xue C, Li S, Zao X, Li X, Liu Q, et al. Liver cirrhosis: current status and treatment options using western or traditional Chinese medicine. Frontiers in Pharmacology. 2024; 15: 1381476.

[23] Wang X, Zeng X, Wang G. External treatment of refractory ascites induced by liver cirrhosis by traditional Chinese medicine. Asian Journal of Surgery. 2024; 47: 4429–4430.

[24] Ding R, Xie W, Jia J, Wang Q. FRI-114 Entecavir can significantly improve the prognosis of patients with first decompensated hepatitis B cirrhosis. Journal of Hepatology. 2024; 80: S228–S229.

[25] Li Y, Zhu Y, Gao D, Pan Y, Wang J, Zhang S, et al. HBeAg-positive CHB patients with indeterminate phase associated with a high risk of significant fibrosis. Virology Journal. 2024; 21: 287–287.

[26] Xu T, Lu Z, Xiao Z, Liu F, Chen Y, Wang Z, et al. Myofibroblast induces hepatocyte-to-ductal metaplasia via laminin-ɑvβ6 integrin in liver fibrosis. Cell Death & Disease. 2020; 11: 199.

[27] Gong L, Zhou H, Zhang Y, Wang C, Fu K, Ma C, et al. Preparation of Phillygenin-Hyaluronic acid composite milk-derived exosomes and its anti-hepatic fibrosis effect. Materials Today Bio. 2023; 23: 100804.

[28] Liu Y, Wang Z, Qin X. Metabolomics and molecular docking to compare of the efficacies of wild-simulated and transplanted Astragali Radix based on its compatibility with Angelicae Sinensis Radix against blood deficiency. Journal of Chromatography B. 2021; 1173: 122682.

[29] Bai Y, Chen R, Sun J, Guo Y. Evaluation of therapeutic mechanism of hedyotis diffusa willd (HDW)-scutellaria barbata (SB) in clear cell renal cell carcinoma via singlecell RNA sequencing and network pharmacology. Combinatorial Chemistry & High Throughput Screening. 2024; 27: 910–921.

[30] Dai MX, Shi QX, Xiang XL, Zhao XY, Zeng ZX, Jin SN, et al. Metabolomics study of lipid lowering effect and lysophospholipids regulation by Alismatis rhizoma and processed forms in hyperlipidemia mice. Chinese Journal of Analytical Chemistry. 2024; 52: 100431.

[31] Huang Y, You J, Jing R, He Y, Li X, Wen Y, et al. Mechanisms of Salvia miltiorrhiza and Angelica sinensis herbal pair in intervening ischemic stroke based on network pharmacology and molecular docking. Frontiers in Medical Science Research. 2023; 5: 1–11.

[32] Zhan D, Li Y, Xu L, Li Y, Song M, Yi W, et al. Fuling Guizhi Baizhu Gancao Decoction combined with traditional Chinese medicine and acupoint injection in the treatment of refractory ascites in patients with hepatitis B-related cirrhosis. Panminerva Medica. 2024; 66: 207–209.

[33] Li Z, Dong M, Chen Z, Zhang C, Jiang J, Liu M, et al. Combining virus-based affinity ultrafiltration method with serum pharmacochemistry to identify the antiviral pharmacodynamic substances in licorice. Journal of Ethnopharmacology. 2024; 338: 118978.

[34] Liu A, Sun J, Tiwari S, Wong J, Wang H, Tang D, et al. Effect of Chinese herbal formulae (BU-SHEN-YI-QI granule) treatment on thrombin expression after ischemia/reperfusion. All Life. 2023; 16: 2173311.

[35] Wu X, Zhou J, Xie W, Ding H, Ou X, Chen G, et al. Entecavir monotherapy versus de novo combination of lamivudine and adefovir for compensated hepatitis B virus-related cirrhosis: a real-world prospective multicenter cohort study. Infect Drug Resist. 2019; 12: 745–757.